HPV Vaccination Training of Healthcare Providers and Perceived Self-Efficacy in HPV Vaccine-Hesitancy Counseling
Abstract
:1. Introduction
2. Methods
Study Design, Data Source, and Population
3. Measures
3.1. Dependent Variables
HCP’s Perceived Self-Efficacy or Confidence in HPV Vaccine-Hesitancy Counseling
3.2. Independent Variable
3.2.1. Training of HCPs
3.2.2. HCP Socio-Demographic and Practice-Related Factors
3.2.3. Data Analysis
4. Results
4.1. HCPs’ Perceived Self-Efficacy in Counseling HPV Vaccine-Hesitant Parents of Pediatric Patients (9–18 Years)
4.2. HCPs’ Perceived Self-Efficacy in Counseling HPV Vaccine-Hesitant Adult Patients (>18 Years)
5. Discussion
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Meites, E.; Gee, J.; Unger, E.; Markowitz, L. Human papillomavirus. In Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th ed.; Hamborsky, J., Ed.; Centers for Disease Control and Prevention, USA. 2015; pp. 175–186. Available online: https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html#hpv (accessed on 14 June 2022).
- De Martel, C.; Plummer, M.; Vignat, J.; Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer 2017, 141, 664–670. [Google Scholar] [CrossRef] [Green Version]
- Bosch, F.X.; Lorincz, A.; Muñoz, N.; Meijer, C.J.L.M.; Shah, K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55, 244–265. [Google Scholar] [CrossRef] [Green Version]
- Texas Department of State Health Services. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch. HPV-Associated Cancers in Texas, 2013–2017. Austin, TX. 2020. Available online: https://www.dshs.state.tx.us/tcr/data/modifiable/HPV-Associated-Cancers-in-Texas.pdf. (accessed on 14 June 2022).
- Bruni, L.; Albero, G.; Serrano, B.; Mena, M.; Gómez, D.; Muñoz, J.; Bosch, F.X.; De Sanjosé, S.; ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in United States of America. Summary Report 22 October 2021. Available online: https://hpvcentre.net/statistics/reports/USA.pdf?t=1637096150704 (accessed on 29 June 2022).
- Centers for Disease Control and Prevention. HPV Vaccine Safety and Effectiveness Data. Available online: https://www.cdc.gov/hpv/hcp/vaccine-safety-data.html. (accessed on 14 June 2022).
- Sonawane, K.; Lin, Y.Y.; Damgacioglu, H.; Zhu, Y.; Fernandez, M.E.; Montealegre, J.R.; Cazaban, C.G.; Li, R.; Lairson, D.R.; Lin, Y.; et al. Trends in human papillomavirus vaccine safety concerns and adverse event reporting in the United States. JAMA Netw. Open 2021, 4, e2124502. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, K.H.; Santibanez, T.A.; Stokley, S.; Lindley, M.C.; Fisher, A.; Kim, D.; Greby, S.; Srivastav, A.; Singleton, J. Parental vaccine hesitancy and its association with adolescent HPV vaccination. Vaccine 2021, 39, 2416–2423. [Google Scholar] [CrossRef]
- Robles, C.; Bruni, L.; Acera, A.; Riera, J.C.; Prats, L.; Poljak, M.; Mlakar, J.; Valenčak, A.O.; Eriksson, T.; Lehtinen, M.; et al. Determinants of human papillomavirus vaccine uptake by adult women attending cervical cancer screening in 9 European countries. Am. J. Prev. Med. 2021, 60, 478–487. [Google Scholar] [CrossRef]
- Sonawane, K.; Zhu, Y.; Lin, Y.Y.; Damgacioglu, H.; Lin, Y.; Montealegre, J.R.; Deshmukh, A.A. HPV vaccine recommendations and parental intent. Pediatrics 2021, 147, 1. [Google Scholar] [CrossRef] [PubMed]
- Elam-Evans, L.D.; Yankey, D.; Singleton, J.A.; Sterrett, N.; Markowitz, L.E.; Williams, C.L.; Fredua, B.; McNamara, L.; Stokley, S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2020. Morb. Mortal. Wkly. Rep. 2021, 70, 1183–1190. [Google Scholar] [CrossRef]
- Szilagyi, P.G.; Albertin, C.S.; Gurfinkel, D.; Saville, A.W.; Vangala, S.; Rice, J.D.; Helmkamp, L.; Zimet, G.D.; Valderrama, R.; Breck, A.; et al. Prevalence and characteristics of HPV vaccine hesitancy among parents of adolescents across the US. Vaccine 2020, 38, 6027–6037. [Google Scholar] [CrossRef]
- Vu, M.; King, A.R.; Jang, H.M.; Bednarczyk, R.A. Practice-, provider- and patient-level facilitators of and barriers to HPV vaccine promotion and uptake in Georgia: A qualitative study of healthcare providers’ perspectives. Health Educ. Res. 2020, 35, 512–523. [Google Scholar] [CrossRef]
- McRee, A.; Gilkey, M.B.; Dempsey, A.F. HPV vaccine hesitancy: Findings from a statewide survey of health care providers. J. Pediatr. Health Care 2014, 28, 541–549. [Google Scholar] [CrossRef]
- Kulczycki, A.; Qu, H.; Shewchuk, R. Primary care physicians’ adherence to guidelines and their likelihood to prescribe HPV vaccine for 11–12 year-old girls. Women’s Health Issues 2015, 26, 34–39. [Google Scholar] [CrossRef] [Green Version]
- Lin, C.; Mullen, J.; Smith, D.; Kotarba, M.; Kaplan, S.J.; Tu, P. Healthcare providers’ vaccine perceptions, hesitancy, and recommendation to patients: A systematic review. Vaccines 2021, 9, 713. [Google Scholar] [CrossRef]
- Hansen, K.; Ward, M.; Avashia, S.; Duc, J.; Spielberg, F. What impacts HPV vaccination recommendations? An exploration of medical residents’ knowledge, training, barriers, and practices. Fam. Med. 2020, 52, 745–751. [Google Scholar] [CrossRef]
- Shawhan, A.; Ruppe, R.L. Increasing human papillomavirus vaccination rates among adolescents: Overcoming vaccine hesitancy and using practice improvements. J. Nurse Pract. 2019, 15, 559–563. [Google Scholar] [CrossRef]
- Gallagher, M.W. Self-efficacy. In Encyclopedia of Human Behavior, 2nd ed.; Ramachandran, V.S., Ed.; Academic Press: San Diego, CA, USA, 2012; pp. 314–320. Available online: https://www.sciencedirect.com/science/article/pii/B9780123750006003128 (accessed on 14 June 2022).
- Brewer, N.T.; Hall, M.E.; Malo, T.L.; Gilkey, M.B.; Quinn, B.; Lathren, C. Announcements versus conversations to improve HPV vaccination coverage: A randomized trial. Pediatrics 2017, 139, e20161764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malo, T.L.; Hall, M.E.; Brewer, N.T.; Lathren, C.R.; Gilkey, M.B. Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation. Implement. Sci. IS 2018, 13, 57. [Google Scholar] [CrossRef]
- Dempsey, A.F.; Pyrznawoski, J.; Lockhart, S.; Barnard, J.; Campagna, E.J.; Garrett, K.; Fisher, A.; Dickinson, L.M.; O’Leary, S.T. Effect of a health care professional communication training intervention on adolescent human papillomavirus vaccination: A cluster randomized clinical trial. JAMA Pediatr. 2018, 172, e180016. [Google Scholar] [CrossRef]
- LexisNexis. Master Provider Referential Database. Available online: https://risk.lexisnexis.com/ (accessed on 10 March 2022).
- Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. PLoS Med. 2007, 370, 1453–1457. [Google Scholar] [CrossRef] [Green Version]
- U.S. Department of Agriculture. Rural-Urban Continuum Codes. Available online: https://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx (accessed on 20 June 2022).
- Leung, S.O.A.; Akinwunmi, B.; Elias, K.M.; Feldman, S. Educating healthcare providers to increase human papillomavirus (HPV) vaccination rates: A qualitative systematic review. Vaccine X 2019, 3, 100037. [Google Scholar] [CrossRef]
- Rosenthal, S.L.; Weiss, T.W.; Zimet, G.D.; Ma, L.; Good, M.B.; Vichnin, M.D. Predictors of HPV vaccine uptake among women aged 19–26: Importance of a physician’s recommendation. Vaccine 2009, 29, 890–895. [Google Scholar] [CrossRef]
- Oh, N.L.; Biddell, C.B.; Rhodes, B.E.; Brewer, N.T. Provider communication and HPV vaccine uptake: A meta-analysis and systematic review. Prev. Med. 2021, 148, 106554. [Google Scholar] [CrossRef]
- Cotter, J.C.; Wilson, K.J.; Mallonee, L.F. Impact of HPV immunization training on dental hygiene students’ attitudes and confidence regarding HPV preventive education. J. Dent. Educ. 2020, 84, 88–93. [Google Scholar] [CrossRef]
- McFadden, S.M.; Ko, L.K.; Shankar, M.; Ibrahim, A.; Berliner, D.; Lin, J.; Mohamed, F.B.; Amsalu, F.; Ali, A.A.; Jang, S.H.; et al. Development and evaluation of an online continuing education course to increase healthcare provider self-efficacy to make strong HPV vaccine recommendations to east African immigrant families. Tumour Virus Res. 2021, 11, 200214. [Google Scholar] [CrossRef] [PubMed]
- Reno, J.E.; O’leary, S.; Garrett, K.; Pyrzanowski, J.; Lockhart, S.; Campagna, E.; Barnard, J.; Dempsey, A.F. Improving provider communication about HPV vaccines for vaccine-hesitant parents through the use of motivational interviewing. J. Health Commun. 2018, 23, 313–320. [Google Scholar] [CrossRef]
- Chido-Amajuoyi, O.G.; Talluri, R.; Shete, S.S.; Shete, S. Safety concerns or adverse effects as the main reason for human papillomavirus vaccine refusal: National Immunization Survey–Teen, 2008 to 2019. JAMA Pediatr. 2021, 175, 1074–1076. [Google Scholar] [CrossRef] [PubMed]
- Fokom Domgue, J.; Cunningham, S.A.; Yu, R.K.; Shete, S. Reasons for not receiving the HPV vaccine among eligible adults: Lack of knowledge and of provider recommendations contribute more than safety and insurance concerns. Cancer Med. 2020, 9, 5281–5290. [Google Scholar] [CrossRef]
- Elam-Evans, L.D.; Yankey, D.; Singleton, J.A.; Sterrett, N.; Markowitz, L.E.; Williams, C.L.; Fredua, B.; McNamara, L.; Stokley, S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2019. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1109–1116. [Google Scholar] [CrossRef]
- Chen, M.M.; Mott, N.; Clark, S.J.; Harper, D.M.; Shuman, A.G.; Prince, M.E.; Dossett, L.A. HPV vaccination among young adults in the US. JAMA J. Am. Med. Assoc. 2021, 325, 1673–1674. [Google Scholar] [CrossRef] [PubMed]
- Lewis, R.M.; Markowitz, L.E. Disparities in human papillomavirus vaccination coverage in the United States, national health and nutrition examination survey, January 2017–March 2020. Vaccine 2022, 40, 2828–2832. [Google Scholar] [CrossRef]
- Rand, C.M.; Schaffer, S.J.; Dhepyasuwan, N.; Blumkin, A.; Albertin, C.; Serwint, J.R.; Darden, P.M.; Humiston, S.G.; Mann, K.J.; Stratbucker, W.; et al. Provider communication, prompts, and feedback to improve HPV vaccination rates in resident clinics. Pediatrics 2018, 141, e20170498. [Google Scholar] [CrossRef]
- Fiorito, T.M.; Krilov, L.R.; Nonaillada, J. Human papillomavirus knowledge and communication skills: A role-play activity for providers. MedEdPORTAL 2021, 17, 11150. [Google Scholar] [CrossRef] [PubMed]
- Bandura, A. Self-efficacy: Toward a unifying theory of behavioral change. Psychol. Rev. 1977, 84, 191–215. [Google Scholar] [CrossRef] [PubMed]
- Cook, D.A.; Wittich, C.M.; Daniels, W.L.; West, C.P.; Harris, A.M.; Beebe, T.J. Incentive and reminder strategies to improve response rate for internet-based physician surveys: A randomized experiment. J. Med. Internet Res. 2016, 18, e244. [Google Scholar] [CrossRef] [PubMed]
HCPs’ Perceived Self-Efficacy in Counseling HPV Vaccine-Hesitant Parents of Pediatric Patients (9–18 Years) (n = 577) | HCPs’ Perceived Self-Efficacy in Counseling HPV Vaccine-Hesitant Adult Patients (>18 Years) (n = 505) | |||||
---|---|---|---|---|---|---|
HCP Characteristics | Not at All/ Somewhat/ Moderate (n = 172) | Very/ Completely (n = 405) | p-Value | Not at All/ Somewhat/ Moderate (n = 190) | Very/ Completely (n = 315) | p-Value |
Training, n (%) | <0.001 | <0.001 | ||||
No | 103 (41.4) | 146 (58.6) | 119 (51.5) | 112 (48.5) | ||
Yes | 68 (20.9) | 257 (79.1) | 70 (25.8) | 201 (74.2) | ||
Provider age, years, n (%) | 0.002 | 0.001 | ||||
< 35 | 28 (46.7) | 32 (53.3) | 37 (57.8) | 27 (42.2) | ||
35–54 | 108 (29.7) | 256 (70.3) | 112 (36.7) | 193 (63.3) | ||
≥ 55 | 33 (22.3) | 115 (77.7) | 38 (29.7) | 90 (70.3) | ||
Sex, n (%) | 0.958 | 0.689 | ||||
Female | 128 (29.8) | 302 (70.2) | 140 (37.1) | 237 (62.9) | ||
Male | 42 (30.0) | 98 (70.0) | 47 (39.2) | 73 (60.8) | ||
Race/Ethnicity, n (%) | 0.375 | 0.013 | ||||
Non-Hispanic White | 79 (27.8) | 205 (72.2) | 83 (32.7) | 171 (67.3) | ||
Non-Hispanic Black | 13 (26.5) | 36 (73.5) | 24 (51.1) | 23 (48.9) | ||
Hispanic | 28 (30.8) | 63 (69.2) | 24 (32.4) | 50 (67.6) | ||
Non-Hispanic Other | 49 (35.8) | 88 (64.2) | 55 (46.2) | 64 (53.8) | ||
Practice location, n (%) | 0.49 | 0.053 | ||||
Rural | 7 (24.1) | 22 (75.9) | 6 (20.7) | 23 (79.3) | ||
Urban | 165 (30.2) | 382 (69.8) | 184 (38.7) | 292 (61.3) | ||
Provider type, n (%) | 0.048 | 0.455 | ||||
Physician | 89 (25.6) | 259 (74.4) | 84 (35.0) | 156 (65.0) | ||
Nurse | 52 (37.1) | 88 (62.9) | 63 (38.2) | 102 (61.8) | ||
Physician Assistant | 22 (33.3) | 44 (66.7) | 31 (40.8) | 45 (59.2) | ||
Other | 9 (39.1) | 14 (60.9) | 12 (50.0) | 12 (50.0) | ||
Type of practice, n (%) | 0.092 | 0.702 | ||||
University/Teaching hospital | 51 (39.2) | 79 (60.8) | 55 (40.4) | 81 (59.6) | ||
Solo practice | 16 (26.2) | 45 (73.8) | 19 (44.2) | 24 (55.8) | ||
Group practice | 69 (28.9) | 170 (71.1) | 66 (36.9) | 113 (63.1) | ||
FQHC/Public facility | 20 (25.0) | 60 (75.0) | 28 (35.0) | 52 (65.0) | ||
Other | 16 (23.9) | 51 (76.1) | 22 (32.8) | 45 (67.2) | ||
Years in practice, n (%) | <0.001 | <0.001 | ||||
≤10 years | 77 (39.5) | 118 (60.5) | 89 (47.1) | 100 (52.9) | ||
11–20 years | 63 (31.2) | 139 (68.8) | 65 (38.9) | 102 (61.1) | ||
>20 years | 31 (17.5) | 146 (82.5) | 33 (22.9) | 111 (77.1) | ||
No. of patients seen (per week), n (%) | <0.001 | <0.001 | ||||
≤50 | 84 (43.1) | 111 (56.9) | 95 (49.5) | 97 (50.5) | ||
51–100 | 68 (24.3) | 212 (75.7) | 70 (28.0) | 180 (72.0) | ||
>100 | 17 (18.7) | 74 (81.3) | 20 (37.0) | 34 (63.0) |
HCP Characteristics | Crude OR (95% CI) | p-Value | Adjusted OR (95% CI) | p-Value |
---|---|---|---|---|
Training | ||||
No | Ref | Ref | Ref | Ref |
Yes | 2.67 (1.85–3.85) | <0.001 | 2.56 (1.69–3.86) | <0.001 |
Provider age, years | ||||
<35 | Ref | Ref | Ref | Ref |
35–54 | 2.07 (1.19–3.61) | 0.01 | 1.57 (0.78–3.14) | 0.205 |
≥55 | 3.05 (1.61–5.77) | 0.001 | 0.91 (0.34–2.41) | 0.843 |
Sex | ||||
Female | Ref | Ref | Ref | Ref |
Male | 0.99 (0.65–1.50) | 0.958 | 0.66 (0.40–1.09) | 0.106 |
Race/Ethnicity | ||||
Non-Hispanic White | Ref | Ref | Ref | Ref |
Non-Hispanic Black | 1.07 (0.54–2.12) | 0.852 | 1.34 (0.60–3.00) | 0.476 |
Hispanic | 0.87 (0.52–1.45) | 0.587 | 0.84 (0.46–1.51) | 0.552 |
Non-Hispanic Other | 0.69 (0.45–1.07) | 0.097 | 0.73 (0.45–1.21) | 0.225 |
Practice location | ||||
Rural | Ref | Ref | Ref | Ref |
Urban | 0.74 (0.31–1.76) | 0.491 | 0.74 (0.28–1.93) | 0.533 |
Provider type | ||||
Physician | Ref | Ref | Ref | Ref |
Nurse | 0.58 (0.38–0.88) | 0.011 | 0.48 (0.29–0.80) | 0.004 |
Physician Assistant | 0.69 (0.39–1.21) | 0.194 | 0.71 (0.36–1.38) | 0.307 |
Other | 0.53 (0.22–1.28) | 0.159 | 1.05 (0.39–2.84) | 0.926 |
Type of practice | ||||
University/Teaching hospital | Ref | Ref | Ref | Ref |
Solo practice | 1.82 (0.93–3.55) | 0.081 | 1.49 (0.68–3.27) | 0.318 |
Group practice | 1.59 (1.01–2.49) | 0.043 | 1.19 (0.69–2.04) | 0.534 |
FQHC/Public facility | 1.94 (1.05–3.59) | 0.036 | 1.95 (0.97–3.91) | 0.062 |
Other | 2.06 (1.06–3.99) | 0.033 | 1.81 (0.85–3.88) | 0.124 |
Years in practice | ||||
≤10 years | Ref | Ref | Ref | Ref |
11–20 years | 1.44 (0.95–2.18) | 0.084 | 1.20 (0.72–2.01) | 0.488 |
>20 years | 3.07 (1.90–4.98) | <0.001 | 3.95 (1.80–8.67) | 0.001 |
No. of patients seen (per week) | ||||
≤50 | Ref | Ref | Ref | Ref |
51–100 | 2.36 (1.59–3.50) | <0.001 | 2.32 (1.48–3.63) | <0.001 |
>100 | 3.29 (1.81–5.99) | <0.001 | 3.97 (1.95–8.09) | <0.001 |
HCP Characteristics | Crude OR (95% CI) | p-Value | Adjusted OR (95% CI) | p-Value |
---|---|---|---|---|
Training | ||||
No | Ref | Ref | Ref | Ref |
Yes | 3.05 (2.10–4.44) | <0.001 | 2.84 (1.87–4.33) | <0.001 |
Provider age, years | ||||
<35 | Ref | Ref | Ref | Ref |
35–54 | 2.36 (1.37–4.08) | 0.002 | 1.98 (1.00–3.93) | 0.05 |
≥55 | 3.25 (1.74–6.06) | <0.001 | 0.72 (0.26–1.99) | 0.522 |
Sex | ||||
Female | Ref | Ref | Ref | Ref |
Male | 0.92 (0.60–1.40) | 0.689 | 0.87 (0.52–1.46) | 0.605 |
Race/Ethnicity | ||||
Non-Hispanic White | Ref | Ref | Ref | Ref |
Non-Hispanic Black | 0.47 (0.25–0.87) | 0.017 | 0.56 (0.27–1.18) | 0.129 |
Hispanic | 1.01 (0.58–1.76) | 0.968 | 1.17 (0.62–2.20) | 0.626 |
Non-Hispanic Other | 0.56 (0.36–0.88) | 0.012 | 0.61 (0.36–1.03) | 0.066 |
Practice location | ||||
Rural | Ref | Ref | Ref | Ref |
Urban | 0.41 (0.17–1.04) | 0.059 | 0.41 (0.15–1.12) | 0.081 |
Provider type | ||||
Physician | Ref | Ref | Ref | Ref |
Nurse | 0.87 (0.58–1.32) | 0.513 | 0.77 (0.47–1.28) | 0.316 |
Physician Assistant | 0.78 (0.46–1.33) | 0.361 | 0.72 (0.38–1.36) | 0.31 |
Other | 0.54 (0.23–1.25) | 0.15 | 0.77 (0.29–2.01) | 0.589 |
Type of practice | ||||
University/Teaching hospital | Ref | Ref | Ref | Ref |
Solo practice | 0.86 (0.43–1.71) | 0.664 | 0.54 (0.24–1.23) | 0.14 |
Group practice | 1.16 (0.74–1.84) | 0.519 | 0.76 (0.43–1.34) | 0.34 |
FQHC/Public facility | 1.26 (0.71–2.24) | 0.428 | 0.94 (0.47–1.86) | 0.85 |
Other | 1.39 (0.75–2.57) | 0.295 | 0.95 (0.47–1.92) | 0.891 |
Years in practice | ||||
≤10 years | Ref | Ref | Ref | Ref |
11–20 years | 1.40 (0.92–2.13) | 0.121 | 1.01 (0.59–1.73) | 0.966 |
>20 years | 2.99 (1.85–4.85) | <0.001 | 4.72 (1.99–11.15) | <0.001 |
No. of patients seen (per week) | ||||
≤50 | Ref | Ref | Ref | Ref |
51–100 | 2.52 (1.70–3.74) | <0.001 | 2.94 (1.85–4.66) | <0.001 |
>100 | 1.66 (0.90–3.10) | 0.107 | 2.10 (0.98–4.50) | 0.055 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Osaghae, I.; Darkoh, C.; Chido-Amajuoyi, O.G.; Chan, W.; Padgett Wermuth, P.; Pande, M.; Cunningham, S.A.; Shete, S. HPV Vaccination Training of Healthcare Providers and Perceived Self-Efficacy in HPV Vaccine-Hesitancy Counseling. Vaccines 2022, 10, 2025. https://doi.org/10.3390/vaccines10122025
Osaghae I, Darkoh C, Chido-Amajuoyi OG, Chan W, Padgett Wermuth P, Pande M, Cunningham SA, Shete S. HPV Vaccination Training of Healthcare Providers and Perceived Self-Efficacy in HPV Vaccine-Hesitancy Counseling. Vaccines. 2022; 10(12):2025. https://doi.org/10.3390/vaccines10122025
Chicago/Turabian StyleOsaghae, Ikponmwosa, Charles Darkoh, Onyema Greg Chido-Amajuoyi, Wenyaw Chan, Paige Padgett Wermuth, Mala Pande, Sonia A. Cunningham, and Sanjay Shete. 2022. "HPV Vaccination Training of Healthcare Providers and Perceived Self-Efficacy in HPV Vaccine-Hesitancy Counseling" Vaccines 10, no. 12: 2025. https://doi.org/10.3390/vaccines10122025
APA StyleOsaghae, I., Darkoh, C., Chido-Amajuoyi, O. G., Chan, W., Padgett Wermuth, P., Pande, M., Cunningham, S. A., & Shete, S. (2022). HPV Vaccination Training of Healthcare Providers and Perceived Self-Efficacy in HPV Vaccine-Hesitancy Counseling. Vaccines, 10(12), 2025. https://doi.org/10.3390/vaccines10122025